Gabriel M.I. Mecklenburg

Director Gabriel M.I. Mecklenburg sold 50,000 shares at $65.53–$66.00 under 10b5-1 plan; retains 1,727,341 derivative shares

Director Gabriel M.I. Mecklenburg executed 2 sales totaling 50,000 shares for $3,276,843.09 on 2026-06-05 under a pre-arranged 10b5-1 trading plan adopted on 2025-12-01. This represents a scheduled transaction, not a discretionary decision. The insider retains 1,727,341 Class B Common Stock shares as derivative holdings, so the non-derivative portion was reduced to zero while his overall position remains substantial. His 5 prior HNGE trades (all on 2026-06-01) showed 30-day and 90-day returns ranging from +3.4% to +13.0%, establishing a pattern of selling ahead of near-term appreciation at this ticker. The current price of $63.62 stands at -1.1% from the 52-week high of $64.30, and the stock has posted a 30-day change of +16.0% and a 90-day change of +37.9%, contextualizing the trade within a strong recent momentum period.

Director Gabriel Mecklenburg sells 83,334 shares ($5.0M) in 7 tranches at HNGE under scheduled 10b5-1 plan; retains 1,777,341 derivative shares.

Gabriel M.I. Mecklenburg, a Director at Hinge Health, executed 7 separate sales totaling 83,334 shares for $5,018,132.67 on 2026-06-01 at prices ranging from $55.74 to $61.68, with a blended average of $60.22. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-12-01, meaning it is scheduled rather than discretionary. While the non-derivative holdings reached zero post-transaction, Mecklenburg retains 1,777,341 Class B Common Stock shares in derivative holdings, representing a substantial continued stake in the company. The 30-day and 90-day price appreciation of +20.0% and +28.0% respectively provides context on recent stock momentum, though his prior sales at HNGE have shown mixed near-term outcomes (ranging from -13.4% to +22.4% over 30 days). Hinge Health reported strong fundamentals with annual revenue growth of +50.6% and net income of $35.1M in the latest quarter, though the company was unprofitable over its most recent full fiscal year, warranting continued monitoring of profitability trajectory.

Director Mecklenburg sells 83,333 HNGE shares for $4,482,885.17 via pre-arranged 10b5-1 plan

Gabriel M.I. Mecklenburg, a Director at Hinge Health, completed 3 separate sales totaling 83,333 shares for $4,482,885.17 on 2026-05-26, with a blended average price of $53.79. This transaction was executed under a pre-arranged 10b5-1 trading plan adopted on 2025-12-01, making it a scheduled, non-discretionary sale. The insider retains 1,860,675 derivative Class B Common Stock shares, meaning this represents a reduction of non-derivative holdings only. At HNGE, Mecklenburg's prior 5 sales over the preceding two months showed mixed timing outcomes: two sales realized subsequent 90-day gains of +17.6% and +37.8%, one a 90-day loss of -3.7%, and two others generated gains of +35.8% and +17.7%, indicating his prior sales at this ticker generally preceded near-term price appreciation. The current stock price of $53.58 is 13.8% below the 52-week high of $62.18, though the 30-day and 90-day changes show positive momentum (+19.0% and +22.7% respectively). Company fundamentals show strong recent growth with annual revenue growth of +50.6% and latest quarterly revenue of $182,307,000.00 with net income of $35,128,000.00, though the company was unprofitable over its most recent full fiscal year.

Director Gabriel Mecklenburg converts and immediately sells all 50,000 shares for $2.75M at current price, clearing his entire position.

Director Gabriel Mecklenburg converted 50,000 shares and immediately sold his entire holdings for approximately $2.75 million on the same day, leaving him with zero remaining shares. This is his sixth sale at Hinge Health, following five prior sales dating back to early March. The timing pattern reveals a concerning disconnect: over a 90-day horizon, all five of his previous exits were poorly timed, with the stock gaining after each sale—yet over 30 days, two of those exits preceded declines, suggesting short-term volatility has occasionally rewarded his exits while longer-term trends have consistently worked against them. The current sale occurs as Hinge Health shows mixed financial signals: the company remains unprofitable on an annual basis but posted a profitable latest quarter with strong year-over-year revenue growth, and the stock trades modestly below its 52-week high after a substantial recent rally. Mecklenburg's complete exit after a series of sales that failed to time the longer-term trend raises questions about what has shifted in his perspective, particularly given the company's recent profitability inflection.

Director Mecklenburg sells 33,333 shares of HNGE at $45.05 ($1.5M); derivative conversion—real position in Form 4 Table II not yet populated.

Director Gabriel M.I. Mecklenburg sold 33,333 shares at $45.05 on 2026-04-21, with the transaction classified as a derivative-conversion sale rather than a full position exit. This filing involves conversion of derivative securities, and the insider's actual post-transaction holdings remain unclear pending Form 4 Table II data. Notably, Mecklenburg's prior same-ticker sales at HNGE on 2026-03-06 and 2026-04-01 showed 30-day losses of -13.4% and -14.5%, and his cross-ticker track record averaged -14.0% over 30 days following prior sells. The company's fundamentals show revenue of $154,211,000.00 and recent unprofitability (net income of $-1,844,000.00), though annual revenue growth reached +50.6%, and the stock currently trades at $44.76, -26.1% from its 52-week high of $60.55. The derivative-conversion nature of this transaction requires careful verification of the insider's true remaining position via Form 4 Table II before assessing full context.

Director Mecklenburg sells 50,000 HNGE shares ($1.9M) in 2 transactions; holds no shares post-trade.

Mecklenburg Gabriel M.I., a director at Hinge Health, sold 2 separate batches totaling 50,000 shares (50.0K shares) for $1,922,779.90 on 2026-04-01 via two open-market transactions at $38.45 and $39.02 per share. The form 4 indicates a derivative-conversion transaction, meaning the insider's real equity position resides in Table II (derivative securities), which is not yet populated in this database—therefore the post-transaction zero shares should not be interpreted as a complete exit. The stock is currently trading at $38.98, down 12.1% over the past 30 days and 35.6% below its 52-week high of $60.55. Hinge Health is unprofitable on a full-year basis (net income of $-1.8M in the latest quarter) despite strong revenue growth of 50.6% year-over-year, signaling ongoing profitability challenges amid rapid scaling. The timing relative to price action requires continued monitoring, particularly given the company's fundamental profitability headwinds.

Director Mecklenburg sells all 166,666 shares at avg $45.32; conversion/exercise transaction, not full exit

Director Gabriel M.I. Mecklenburg executed 2 separate sales on 2026-03-06, totaling 166,666 shares for $7,552,645.29 at a blended average price of $45.32. This sale represents conversion of derivative securities (likely from exercise of options or warrants), not a liquidation of existing equity holdings—the insider's real position in derivative securities is recorded in Table II of the Form 4, which is not yet populated in the database. The sales occurred within the stock's 52-week range of $31.17–$60.55, and the current price of $45.97 is near the blended transaction price, suggesting the timing was neither exceptional nor poorly timed. HNGE reported revenue growth of 50.6% annually and is currently unprofitable ($-1.8M net income in the latest quarter), indicating a growth-stage company with ongoing cash-burn profile. The substantial size of these derivative conversion sales ($7.6M in proceeds) warrants investor attention to confirm whether this reflects normal option-exercise activity or signals any change in executive compensation structure or equity incentive plans.